Skip to main content
Smart Investors Daily
LP

NASDAQ · LPCN

Lipocine Inc.

Healthcare · Biotechnology

$1.66

Down-$0.05 (-2.92%)

Updated Nov 17, 2026, 2:59 AM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
17.11M
P/E ratio
-3.79
Dividend yield
0.00%
52-week range
$1.36 – $12.37
Volume
126.77K
Avg. volume
43.6K

Price performance · LPCN

LPCN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

LPCN closed at $1.66 after 21 trading sessions, up 8.50% for the selected period.

Last close
$1.66
Period change
+8.50%
Period low
$1.44
Period high
$1.72
Daily close
View OHLC price history
LPCN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$1.71$1.75$1.63$1.66126.77K
Nov 13, 2026$1.63$1.75$1.5301$1.71215.11K
Nov 12, 2026$1.58$1.63$1.51$1.6293.62K
Nov 11, 2026$1.62$1.64$1.56$1.59208.11K
Nov 10, 2026$1.66$1.69$1.56$1.59158.54K
Nov 9, 2026$1.60$1.74$1.5801$1.72264.08K
Nov 6, 2026$1.59$1.63$1.50$1.57509.75K
Nov 5, 2026$1.47$1.60$1.4001$1.53417.17K
Nov 4, 2026$1.50$1.50$1.42$1.44108.13K
Nov 3, 2026$1.42$1.50$1.42$1.46188.4K
Nov 2, 2026$1.45$1.47$1.36$1.45248.05K
Oct 30, 2026$1.50$1.50$1.42$1.44112.05K
Oct 29, 2026$1.51$1.56$1.50$1.52139.13K
Oct 28, 2026$1.46$1.54$1.46$1.51194.66K
Oct 27, 2026$1.49$1.49$1.42$1.46129.47K
Oct 26, 2026$1.44$1.45$1.40$1.45108.94K
Oct 23, 2026$1.42$1.48$1.41$1.44218.66K
Oct 22, 2026$1.56$1.60$1.43$1.46354.88K
Oct 21, 2026$1.59$1.64$1.5807$1.60160.67K
Oct 20, 2026$1.54$1.66$1.5374$1.62246.5K
Oct 19, 2026$1.51$1.57$1.40$1.53323.66K

Latest LPCN news

The latest Smart Investors Daily articles mentioning LPCN.

LPCN research

Overview

Company profile and research snapshot.

Company profile

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
LPCN recent ratings
DateFirmRatingTarget
Sep 21, 2026HC Wainwright & Co.Neutral—
Apr 6, 2026HC Wainwright & Co.Neutral—
Jan 21, 2026HC Wainwright & Co.Buy—
Nov 13, 2025HC Wainwright & Co.Buy—
Aug 20, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that the first participant has been dosed in BLOOM, the Company's Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression (PPD). LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use.

Yahoo · Nov 5, 2026

Lipocine: Q3 Earnings Snapshot

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Lipocine Inc. (LPCN) on Thursday reported a loss of $666,000 in its third quarter.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.